Vinorelbine Ditartrate

Small Cell Carcinoma

EpicentRx, Inc.Small moleculePhase 2Dormant

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

18 Active assets in the Small Cell Carcinoma cohort.

Asset / Sponsor	Phase	Rating
NOGITECAN National Cancer Institute (NCI)	Phase 2	BB
Lurbinectedin SystImmune Inc.	Phase 3	BB
CIS-DIAMMINEDICHLOROPLATINUM II EpicentRx, Inc.	Phase 2	BB
ETOPOSIDE SystImmune Inc.	Phase 3	BB
Pembrolizumab Thomas Jefferson University	Phase 2	BB

View all 30 →

Same molecule, other indications

Vinorelbine Ditartrate is also rated in:

Hodgkins lymphomaActive

BBB

Indicative · Phase 3

72 / 100

cervical cancerDormant

BBB

Indicative · Phase 2

72 / 100

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

70 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.